References
- Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017 Jul 4; 70(1): 1–25.
- Mensah GA, Roth GA, Sampson UKA, Moran AE, Feigin VL, Forouzanfar MH, et al. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: A systematic analysis of data from the Global Burden of Disease Study 2013. Cardiovasc J Afr [Internet]. 2015 Mar 1 [cited 2022 Dec 18]; 26(2): S6–10. Available from:
https://pubmed.ncbi.nlm.nih.gov/25962950/ . DOI: 10.5830/CVJA-2015-036 - Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med [Internet]. 2015 Apr 2 [cited 2019 Apr 15]; 372(14): 1333–41. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25830423 . DOI: 10.1056/NEJMoa1406656 - Chacha Mwita J, Godman B. Poverty and cardiovascular diseases in sub-Saharan Africa. In: Lifestyle and Epidemiology – Poverty and Cardiovascular Diseases a Double Burden in African Populations [Working Title] [Internet]; 2021 [cited 2023 Apr 8]. DOI: 10.5772/intechopen.98575
- Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A systematic review of medical costs associated with heart failure in the USA (2014–2020). Pharmacoeconomics [Internet]. 2020 Nov 1 [cited 2023 Apr 2]; 38(11): 1219–36. DOI: 10.1007/s40273-020-00952-0
- Birger M, Kaldjian AS, Roth GA, Moran AE, Dieleman JL, Bellows BK. Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996 to 2016. Circulation [Internet]. 2021 Jul 27 [cited 2023 Apr 2]; 144(4): 271–82. DOI: 10.1161/CIRCULATIONAHA.120.053216
- Adeniji FIP, Obembe TA. Cardiovascular disease and its implication for higher catastrophic health expenditures among households in sub-Saharan Africa. J Heal Econ Outcomes Res. 2023 Mar 17; 10(1). DOI: 10.36469/001c.70252
- United Nations. The Sustainable Development Goals Report. Geneva; 2022.
- Ministry of Finance. The Budget Statement and Economic Policy of the Government of Ghana for the 2023 Financial Year. Accra; 2023.
- Ghana Statistical Services. [Internet]. 2023 [cited 2023 Apr 9]. Available from:
https://statsghana.gov.gh/ . - Ngalesoni F, Ruhago G, Norheim OF, Robberstad B. Economic cost of primary prevention of cardiovascular diseases in Tanzania. Health Policy Plan [Internet]. 2015 Sep 1 [cited 2023 Apr 8]; 30(7): 875–84. DOI: 10.1093/heapol/czu088
- Gaziano TA. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart [Internet]. 2008 Feb 1 [cited 2023 Apr 8]; 94(2): 140–4. Available from:
https://heart.bmj.com/content/94/2/140 . - Ofori-Asenso R, Garcia D. Cardiovascular diseases in Ghana within the context of globalization. Cardiovasc Diagn Ther [Internet]. 2016 Feb [cited 2019 Mar 24]; 6(1): 67–77. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26885494 . - Shrank WH, Deparle NA, Gottlieb S, Jain SH, Orszag P, Powers BW, et al. Health costs and financing: Challenges and strategies for a new administration. Health Aff (Millwood) [Internet]. 2021 Feb 1 [cited 2023 Apr 8]; 40(2): 235–42. DOI: 10.1377/hlthaff.2020.01560
- Adeniji FIP, Lawanson AO, Osungbade KO. The microeconomic impact of out-of-pocket medical expenditure on the households1040147 of cardiovascular disease patients in general and specialized heart hospitals in Ibadan, Nigeria. PLoS One [Internet]. 2022 Jul 1 [cited 2023 Apr 8]; 17(7 July):
e0271568 . DOI: 10.1371/journal.pone.0271568 - Catharina de Beer J, Snyman J, Ker J, Miller-Janson H, Stander M. Budget impact analysis of empagliflozin in the treatment of patients with type 2 diabetes with established cardiovascular disease in South Africa. Value Heal Reg Issues. 2023 Jan 1; 33: 91–8. DOI: 10.1016/j.vhri.2022.08.012
- Abushanab D, Al-Badriyeh D, Liew D, Ademi Z. First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in Qatar. A cost-effectiveness analysis. Curr Probl Cardiol. 2022 Jun 1; 47(6): 100852. DOI: 10.1016/j.cpcardiol.2021.100852